Clinical Trials Browser

Phase 1/2 × Solid Tumor × LY-2157299 × Clear all

NCT02423343 2021-09-09

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Phase 1/2 Completed

41 enrolled 21 charts

GastrointestinalOther solid neoplasmThoracic

Solid Tumor